Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for Alzheimer’s disease, a new study shows.

Type-2 diabetes patients taking the active ingredient in the drugs, semaglutide, "had a significantly lower risk" of developing the disease, the study found

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.

Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared to patients taking seven other diabetes drugs, researchers reported.

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.